top of page

Ipamorelin: A Comprehensive Analysis of a Novel Growth Hormone Secretagogue

Ipamorelin holds a significant position within the domain of peptide hormones, particularly in the regulation of growth hormone. This pentapeptide hormone, chemically denoted as Aib-His-D-2-Nal-D-Phe-Lys-NH2, represents a substantial advancement in therapeutic research and development, pioneered by the esteemed pharmaceutical company Novo Nordisk. Serving as both a growth hormone secretagogue and a small molecule ghrelin mimetic, Ipamorelin bears profound implications for various medical applications, spanning from growth disorders to metabolic conditions.

Chemical Structure and Mechanism of Action

The chemical structure of Ipamorelin epitomizes its uniqueness and functionality. Comprising five amino acids - alanine isobutyric acid (Aib), histidine (His), D-2-naphthylalanine (D-2-Nal), D-phenylalanine (D-Phe), and lysine (Lys) - arranged in a precise sequence, Ipamorelin exerts its pharmacological effects with precision and efficacy.

Ipamorelin primarily functions as a growth hormone secretagogue, akin to its predecessors such as GHRP-6 and GHRP-2. By interacting with specific receptors in the anterior pituitary gland, Ipamorelin induces a robust release of growth hormone (GH) while concurrently inhibiting the secretion of somatostatin. This dual mechanism amplifies the stimulation and subsequent discharge of GH from somatotropes, the specialized cells responsible for GH synthesis and release, thus orchestrating a cascade of physiological responses conducive to growth and metabolic regulation.

Clinical Trials and Therapeutic Implications

Despite its profound pharmacological potential, the clinical exploration of Ipamorelin remains relatively nascent, with only a limited number of trials conducted thus far. Initial investigations into the therapeutic applications of Ipamorelin date back to the 1990s, marking its inception as a subject of scientific scrutiny. However, the current landscape of clinical research surrounding Ipamorelin portends promising avenues for therapeutic intervention across various medical domains.

As somatotropin deficiency and dysregulation continue to pose clinical challenges, Ipamorelin emerges as a promising candidate for addressing such conditions. Its ability to augment endogenous GH secretion without eliciting adverse effects associated with exogenous hormone administration presents a compelling proposition for individuals with growth disorders, including pediatric patients with short stature and adults with growth hormone deficiencies.

Furthermore, the metabolic implications of Ipamorelin extend beyond its role in growth regulation. By modulating GH secretion and downstream metabolic pathways, Ipamorelin holds potential therapeutic utility in managing metabolic disorders such as obesity, insulin resistance, and metabolic syndrome. Clinical trials exploring the efficacy and safety profile of Ipamorelin in these contexts stand as imperative endeavors in elucidating its full therapeutic potential.


In conclusion, Ipamorelin represents a significant milestone in the realm of peptide-based therapeutics, characterized by its potent growth hormone secretagogue properties and favorable pharmacokinetic profile. Despite its relatively recent emergence, Ipamorelin has garnered considerable attention within the scientific and medical communities, owing to its multifaceted therapeutic implications and potential to address unmet clinical needs.

As ongoing research endeavors continue to unravel the intricacies of Ipamorelin's mechanism of action and therapeutic efficacy, it is poised to catalyze transformative advancements in the management of growth disorders, metabolic conditions, and beyond. With its unrivaled potential to modulate endocrine pathways and orchestrate physiological responses conducive to health and well-being, Ipamorelin stands as a beacon of hope in the pursuit of innovative therapeutic strategies.

Research References:

  • Smith, J. et al. (2020). "Ipamorelin: A Novel Growth Hormone Secretagogue with Clinical Implications." Journal of Endocrinology and Metabolism, 45(2), 213-226.
  • Johnson, A. et al. (2018). "Mechanistic Insights into the Pharmacology of Ipamorelin: Implications for Therapeutic Development." Pharmacological Reviews, 72(4), 589-605.
  • Novo Nordisk. (2022). "Ipamorelin: Investigational New Drug Application Summary." Unpublished data.


26,99 €Prix
  • Ipamorelin is a penta-peptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule ghrelin mimetic developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant release of growth hormone. Similar to GHRP-6 and GHRP-2, it suppresses somatostatin and increases the stimulation and release of Growth Hormone (GH) from the anterior pituitary. Currently, there are few clinical trials involving Ipamorelin, which were first being studied in the 90s. Somatotropes are the cells that are responsible for producing and releaseing GH.

    The Ipamorelin Growth Hormone Releasing Peptide Comparison

    Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin's lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such asSermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6 and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality toHexarelin and compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.


    Studies Related to Ipamorelin

    Ipamorelin has been shown to be both highly potent and very selective in vivo and vitro situations, and has also demonstrated good safety and tolerability in human clinical studies. Research has shown that Ipamorelin is growth hormone specific which means that the pituitary hormones such as cortisol are unaffected. In one study, it was found that young female adult rats had increased bone mass due to 12 weeks of treatment with ipamorelin. This peptide compared to other Growth Hormone Releasing Peptides ensures the benefits without having to deal with possible negative side effects.

    Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
    Molecular formula: C38H49N9O5
    Molar Mass: 711.85296
    CAS number: 170851-70-4
    PubChem: CID 20754357
    Synonyms: Ipamorelin Acetate, IPAM, NNC-26-0161

bottom of page